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Abstract
Objective—To assess the extent of long-term morbidity in children with congenital heart disease 
(CHD).
Study Design—We used data from the 1997–2011 National Health Interview Survey to study 
long-term outcomes in children aged 0–17 years with CHD. Parents were asked whether their 
child was diagnosed with CHD. We assessed comorbidities including autism/autism spectrum 
disorders (ASD); healthcare utilization including number of emergency room visits; and daily life 
aspects including number of days of school missed. These outcomes were compared for children 
with and without reports of CHD using odds ratios and chi-squared statistics.
Results—Our study included 420 children with and 180,048 children without reports of CHD; 
with no significant differences in age and sex. The odds of reporting worse health and greater than 
10 days of school/daycare missed in the last year were three times as high for children with CHD 
compared to children without CHD. Children aged 2–17 with CHD were more likely than children 
without CHD to have had a diagnosis of ASD (crude odds ratio [OR]: 4.6, 95% confidence 
interval [CI]: 1.9–11.0), or intellectual disability (OR: 9.1, 95% CI: 5.4–15.4). The prevalence of 
emergency room, home, and doctors' visits were significantly higher in children with CHD 
compared to those without CHD.
Conclusions—Reported adverse outcomes were higher in children with congenital heart 
disease. These findings, particularly those regarding neurodevelopmental outcomes, may be 
helpful for parents, healthcare providers, and others in assessing the specific needs of children and 
teenagers with CHD.
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Introduction
Congenital heart disease (CHD) includes both structural and non-structural anomalies 
present at birth. Structural anomalies of the heart, or congenital heart defects are the most 
common type of birth defect in the United States 1, 2 and the leading cause of infant 
mortality associated with birth defects 3. With new surgical techniques and medical 
therapies, mortality rates have decreased for children with congenital heart defects4, 5; an 
estimated 85% of these children survive into adulthood 6, 7. It was estimated that 650,000 to 
1.3 million adults were living with a congenital heart defect in the United States in 2002 1. 
These survivors are at increased risk of having physical and developmental disabilities 8–11. 
The prevalence and severity of the comorbidities increase with the complexity of the 
defect 12. Given the increases in survival, there are more adults living with CHD who have 
comorbidities and higher hospital admission rates than the general population 13–16. In 
addition, recent literature shows increased risks of neurodevelopmental outcomes including 
difficulties with language, attention, academic achievement, fine and gross motor skills and 
psychosocial factors for children of various ages with CHD17–20.
The National Health Interview Survey (NHIS) includes a representative sample of children 
aged 0–17 years and has included a question about a diagnosis of a congenital heart disease 
for many years. The purpose of our study was to assess social and daily life, comorbidities, 
neurodevelopmental outcomes and healthcare utilization among children with CHD using a 
nationally, representative sample in order to have data that are useful for policy and public 
health/planning prupses in regards to CHDs in children.
Methods
Data Source
We used data from the National Health Interview Survey (NHIS), a cross-sectional study, 
from 1997 through 2011. NHIS is an annual multistage probability sample survey of the 
civilian, noninstitutionalized population of the United States conducted by the National 
Center for Health Statistics (NCHS) of the U.S. Centers for Disease Control and Prevention. 
NHIS conducts computer-assisted personal interviews with three main components: the 
Family Core, the Sample Adult Core, and the Sample Child Core. In addition to these main 
components, there are supplemental sets of questions that are added each year and can differ 
from one year to the next. The Family Core includes an adult from the family who responds 
to the questionnaire as a proxy for the entire family; the Family Core includes questions on 
health status, income and assets, limitations, injuries and more. In addition, the Sample 
Adult Core includes one random adult (18 years or older) and the Sample Child Core 
includes one random child (17 years or younger) from the family for participation. A 
knowledgeable adult in the family answers the questions in the Sample Child Core 
component about the sample child (SC). A series of questions including those on health 
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status, limitations, injuries, healthcare access and utilization, and health insurance are similar 
in the Sample Adult Core and Sample Child Core; however, questions regarding health 
conditions are different and specific to each core. A new sample design was implemented 
for NHIS in 2006, however the fundamental structure was very similar to the previous 
sample design (1995–2005) [http://www.cdc.gov/nchs/nhis/about_nhis.htm]. The NCHS 
Research Ethics Review Board approved the NHANES protocol.
Study sample
The current study includes information collected on all children 0–17 years of age from the 
Sample Child Core component from 1997 to 2011. Children with Down Syndrome (n-298) 
were excluded from our analysis, 21 of whom also had CHD. Information regarding other 
birth defects or genetic syndromes is not available in NHIS. We examined only those 
questions that were relevant to our study objective and were included in years 1997–2011. 
The questions examined for this analysis are included in Appendix A.
Congenital heart disease (CHD)
One of the questions asked in the Sample Child Core component of NHIS was “Has a doctor 
or other health professional ever told you that SC had congenital heart disease?”. There were 
a total of 441 children for whom CHD diagnosis was mentioned (cases) and 180,325 for 
whom this question was answered negatively (controls).
Covariates
Demographic information including age, sex, and race/ethnicity of the SC were reported at 
the time of the interview. We categorized race and ethnicity into the following categories: 
non-Hispanic white, non-Hispanic black, Hispanic and other race/ethnicity. For children 
with and without CHD diagnosis we assessed the following questions: whether health was 
better, worse, or about the same in the last year; days of school (or daycare) missed in the 
last year; special equipment need; impairment or health problem limiting physical activity; 
and whether child has had a problem that requires prescription medication for over three 
months. We also reported on comorbidities including cerebral palsy, sickle cell anemia, 
asthma, allergies, and ear infections. Neurodevelopmental outcomes assessed were autism/
autism spectrum disorders (ASD), Attention-Deficit/Hyperactivity Disorder or Attention-
Deficit Disorder (ADHD/ADD), and intellectual disability. We also examined a variety of 
elements to assess healthcare utilization including number of emergency room visits, home 
care, and frequency of healthcare provider visits in the last year.
Statistical Analysis
Analyses were conducted using SAS (version 9.3; Research Triangle Institute, Research 
Triangle Park, Cary, NC). Survey sample weights and the appropriate sample design 
variables were used in the analysis to account for the complex survey design, oversampling, 
and differential nonresponse and noncoverage, in order to obtain nationally representative 
estimates of the U.S. civilian non-institutionalized population. Taylor series linearization 
method was used to calculate 95% confidence intervals (CIs) for the estimated prevalences, 
and chi-square statistics were used to compare cases to controls.
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We analyzed data on 180,468 children ages 0–17 years, from 1997–2011 with completed 
NHIS interviews: 420 children with reported CHD and 180,048 children without a report of 
CHD. Age and sex distributions were not significantly different for those with CHD 
compared to those without (p=0.99 and p=0.54, respectively); the majority of cases and 
controls were non-Hispanic white (Table 1). When comparing aspects of daily life, cases 
were three times as likely to report worse health in the last year compared to controls (Odds 
Ratio [OR]: 3.3; 95% confidence interval (95% CI): 1.8–6.0) and were also three times as 
likely to have missed more than 10 days of school/day care (OR: 2.9; 95% CI: 2.1–4.1) 
(Table 2). Special equipment use and having an impairment limiting crawling, walking, and 
running were reported more frequently among cases compared to controls (Table 2). Of 
those children with impaired crawling, walking, and running abilities, 98% had impairments 
that had lasted or would last more than 12 months.
Studying other conditions and comorbidities that were queried in NHIS, we found that 
asthma and ear infections (Table 2) and neurodevelopmental issues (Table 3) were reported 
more often for cases than controls. For children under the age of 2 years, respondents for 
cases were as likely to have reported three or more ear infections in the last year compared 
to controls (OR: 2.4; 95% CI: 1.2–5.2) (Table 2). Among neurodevelopmental outcomes in 
children 2–17 years of age, children with CHD diagnoses had higher odds of ASD (OR: 4.6; 
95% CI: 1.9–11.0), ADHD/ADD (OR: 1.6; 95% CI: 1.1–2.4), and intellectual disability 
(OR: 9.1; 95% CI: 5.4–15.4) compared to the controls (Table 3).
We also examined healthcare utilization patterns (Table 3). Children with reported CHD 
were two times as likely than children without CHD to have seen a healthcare professional 
who treated a variety of illnesses in the last year (OR: 1.9; 95% CI: 1.3–2.7). There was a 
significant difference in where the children were taken when sick even though for the 
majority of cases and controls “Doctor’s office” (p<0.0001) was reported. Emergency room 
visits, doctors’ office visits, as well as home care were more common in cases when 
compared to children without CHD diagnosis (Table 3). Furthermore, cases were three times 
as likely to have seen a healthcare provider in the last 12 months compared to controls (OR: 
3.2; 95% CI: 1.7–6.0) and of those children with healthcare provider visits, almost 35% of 
the cases and 16% of the controls visited the healthcare provider more than five times.
Children in all age groups with CHD were more likely to report worse health in the last 12 
months compared to children without CHD (Figure 1). Those 12–17 years of age had the 
highest percentage of school days missed, and the group with the highest need for special 
equipment use were children 6–11 years of age with CHD compared to the other age groups 
(Figure 1). The prevalence of ADHD/ADD, intellectual disability, and learning disability 
increased with increasing age, and all three of these conditions were most commonly noted 
among those 12–17 years of age (Figure 1).
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Using data from the representative National Health Interview Survey, we found that children 
with CHD between the ages of 0 and 17 years are more likely to miss school days and need 
special equipment compared to children without CHD. We found that children with CHD 
are also more likely to have comorbidities including asthma and developmental disabilities 
such as ASD, ADHD/ADD, and intellectual disability. As survival beyond infancy has 
increased, children with CHD appear to be at increased risk for neurodevelopmental and 
psychosocial morbidity, requiring treatment which often affects quality of life as well as 
increased healthcare utilization and cost.
There have been many studies on quality of life (QOL) in children with CHD, including 
congenital heart defects, and their parents 18, 21–26; however, these studies have been in 
select populations and have yielded mixed results. We examined, in NHIS, days of school 
missed, whether health was better or worse in the past year, need of special equipment, and 
impairment limiting physical activity, including crawling, walking, and running, and used 
the information to gain an understanding of daily life for children with CHD. Our finding 
that children with CHD were three times as likely to report declining health in the past year 
and were more likely to miss a greater number of school days, in combination with our 
finding of declining numbers of regular visits with healthcare providers in the older age 
groups, is concerned given that children with CHD should be under routine medical care 27. 
Additionally, an eight-fold increased odds of special equipment need and a fourteen-fold 
increased odds of impairment limiting physical activity are concerning and have 
implications throughout the life of the child and young adult.
In terms of quality of life, another important contributing factor is the presence of other 
comorbidities. To our knowledge, many of the comorbidities including cerebral palsy, sickle 
cell anemia, allergies, and ear infections had not been examined before in association with 
CHD. Our finding that children with CHD had increase prevalence of asthma was similar to 
that of Nieminen et al. 28 in regards to congenital heart defects. Although the numbers of 
cases with cerebral palsy and sickle cell anemia were small, we found higher rates of these 
comorbidities in children with CHD compared to those without CHD. In general, higher 
rates of comorbidities observed in children with CHD compared to those without CHD may 
in part be due to increased healthcare contact for children with CHDs.
Many studies have found increased risks of ASD, ADHD/ADD, and speech and language 
disorders in children with congenital heart defects 29–32. Our results are in agreement with 
recent studies reporting greater prevalences of ASD and attention problems in children with 
congenital heart defects 20, 29–31, 33. We observed an approximate five-fold increases odds 
of ASD and an almost two-fold increased odds of ADHD/ADD in children with CHD 
compared to those without CHD. Our findings support earlier recommendations for careful 
surveillance and screening for these conditions for children with CHD 34. Furthermore, our 
finding that among children with CHD, healthcare utilization was lowest among adolescents 
(12–17) compared to children 0–5 and 6–11 year old is consistent with findings from other 
studies in the United States 35 and in other countries 36–38.
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Strengths of our study are the fact that NHIS provides a large representative sample of the 
non-institutionalized U.S. population with regards to age, geography, and disease severity. 
The large sample size as well as the inclusion of information on comorbidities, including 
neurodevelopmental outcomes, healthcare utilization, and social and daily aspects of the 
child’s life made it possible to assess these important health outcomes in relation to CHD. 
Although the large sample size including 17 years of data is a strength of our study; it could 
affect our findings as we were not able to account for increased awareness of 
neurodevelopmental outcomes or improvements in medical techniques. The main limitation 
of our study is the lack of detail in the question on CHD and the lack of confirmation of the 
diagnosis which could lead to either overestimation or more likely underestimation of the 
prevalence of CHD. The questionnaires did not distinguish whether the congenital heart 
disease was a structural anomaly (congenital heart defect) or nonstructural problem such as 
an arrhythmia. Thus our results do not represent findings for all congenital heart defects or 
for specific types of defects. Furthermore, the questions lacked detail on whether emergency 
room visits or doctor’s visits was due to the CHD or due to an unrelated condition. In 
addition, we were not able to compare our findings for CHD to those of other types of birth 
defects using the National Health Interview Survey because the only types of birth defects 
ascertained were CHD and Down Syndrome. Finally, there was not any information in 
NHIS on any other birth defects and genetic or syndromic conditions; thus the results may 
be biased by subjects having a other conditions such as prematurity or higher incidence of 
underlying genetic abnormalities. To our knowledge this is the first time the CHD question 
from NHIS is being used, and from our analysis it appears to have some limitations. Future 
studies comparing our findings for CHD to those of other defects are warranted.
Overall, we observed greater prevalences of comorbidities, including neurodevelopmental 
disabilities, in children with CHD. Children with CHD were more likely than children 
without CHD to miss school days and utilize healthcare, especially at younger ages. 
Additional information on comorbidities, healthcare utilization, and the impact on the daily 
life of children/adults with CHD would be extremely helpful for patients and their parents as 
they plan for the future as well as for their healthcare providers and public health 
professionals for planning purposes. Thus, pediatricians should be aware that children with 
CHD might need additional care beyond the immediate effects of the CHD and deserve 
close monitoring well beyond early childhood.
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Table 1







  0–5 years 144 (33.4) 61,916 (33.2)
  6–11 years 127 (33.1) 55,487 (33.3)
  12–17 years 149 (33.4) 62,645 (33.5)
P**=0.99
Sex
  Male 216 (49.4) 92,518 (51.1)
  Female 204 (50.6) 87,530 (48.9)
P**=0.54
Race/Ethnicity
  NH White 252 (68.1) 87,993 (59.8)
  NH Black 42 (10.4) 28,055 (14.5)
  Hispanic 97 (15.1) 51,601 (19.1)
  Other 27 (6.3) 11,792 (6.4)
P**=0.05
*
Data source: CDC/NCHS, National Health Interview Survey
**
p-values for χ2 test
CHD: congenital heart disease; NH: non-Hispanic; CDC: Center for Disease Control and Prevention; NCHS: National Center for Health Statistics
Percentages do not correspond with raw numbers because of the weighting used in the National Health Interview Survey (NHIS)
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Table 2
Crude associations for comorbidities and daily life and impairment factors in children 0–17 years for children 







Health in the last 12 months (children aged 2–17 years)
  About the same 237 (93.4) 120,890 (97.9)
3.3 (1.8–6.0)
  Worse 16 (6.6) 2,680 (2.1)
Days of school/day care missed among those who attended school/day care
  ≤10 days 240 (85.9) 117,427 (94.7)
2.9 (2.1–4.1)
  >10 days 47 (14.1) 6,953 (5.3)
Special equipment need due to health problem
  No 386 (92.6) 178,247 (99.0)
8.2 (5.5–12.1)
  Yes 34 (7.4) 1,752 (1.0)
Impairment limits crawl/walk/run
  No 334 (78.7) 176,542 (98.0)
14.1 (10.2–19.4)
  Yes 86 (21.3) 3,431 (1.9)
Cerebral Palsy
  No 411 (98.2) 178,423 (99.0)
1.9 (0.9–4.1)
  Yes 9 (1.8) 1,625 (1.0)
Sickle Cell Anemia
  No 417 (99.4) 179,711 (99.8)
3.7 (0.7–18.8)
  Yes 3 (0.6) 337 (0.2)
Asthma
  No 329 (79.4) 156,820 (87.3)
1.8 (1.3–2.4)
  Yes 90 (20.6) 22,934 (12.7)
    Had an episode in last 12 months 48 (53.0) 9,725 (43.1) 1.5 (0.9–2.5)
Regular intake of prescription medication for over 3 months due to medical problem
  No 283 (67.5) 158,930 (87.8)
3.5 (2.7–4.6)
  Yes 136 (32.5) 20,974 (12.2)
Questions pertaining to children two years of age and younger
72 (%) 32,384 (%)
Allergy (respiratory, food, skin) in last 12 months
  No 45 (76.6) 26,276 (81.8)
1.4 (0.8–2.7)
  Yes 23 (23.4) 5,362 (18.2)
Three or more ear infections in the last 12 months
  No 53 (73.5) 27,739 (87.5)
2.4 (1.2–5.2)
  Yes 15 (26.5) 3,890 (12.5)
*
Data source: CDC/NCHS, National Health Interview Survey
CHD: congenital heart disease; CI: confidence interval; CDC: Center for Disease Control and Prevention; NCHS: National Center for Health 
Statistics
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Table 3
Crude associations between congenital heart disease, neurodevelopmental outcomes, and healthcare utilization 







Neurodevelopmental Outcomes and Healthcare Utilization in children 2–17 years
Autism/ASD
  No 368 (97.4) 157,360 (99.4)
4.6 (1.9–11.0)
  Yes 6 (2.6) 883 (0.6)
ADHD or ADD
  No 329 (89.7) 147,983 (93.4)
1.6 (1.1–2.4)
  Yes 44 (10.3) 9,942 (6.6)
Been told SC had intellectual disability
  No 351 (94.7) 157,146 (99.4)
9.1 (5.4–15.4)
  Yes 23 (5.3) 981 (0.6)
Seen or talked to a mental health professional in last 12 months
  No 317 (85.5) 147,749 (93.5)
2.5 (1.6–3.7)
  Yes 54 (14.5) 9,834 (6.5)
Seen a physical, speech, respiratory, occupational therapist or audiologist in last 12 months
  No 292 (78.4) 148,907 (94.0)
4.3 (3.2–5.9)
  Yes 79 (21.6) 8,657 (6.0)
Learning disability**
  No 271 (79.1) 136,579 (92.4)
3.8 (2.9–5.2)
  Yes 77 (20.9) 10,875 (7.6)







There is a usual place you go to when child is sick
  Yes 400 (96.0) 167,946 (94.3)
0.7 (0.4–1.2)
  No 20 (4.0) 11,777 (5.7)
Has healthcare provider changed in last 12 months
  No 374 (92.0) 154,255 (91.6)
0.9 (0.6–1.4)
  Yes 31 (8.0) 14,203 (8.4)
    Not due to changes in health insurance 23 (82.0) 9,788 (70.6)
0.5 (0.2–1.2)
    Due to changes in health insurance 8 (18.0) 4,401 (29.4)
Has child seen a medical doctor who treats a variety of illnesses^ in last 12 months
  No 52 (12.0) 38,203 (20.2)
1.9 (1.3–2.7)
  Yes 364 (88.0) 140,922 (79.8)
Has child received a well-child checkup in last 12 months
  No 75 (22.6) 36,363 (25.7)
1.2 (0.9–1.6)
  Yes 245 (77.4) 101,699 (74.3)
Has child gone to an ER in last 12 months




















  No 277 (68.4) 141,329 (79.5)
1.8 (1.4–2.4)
  Yes 136 (31.6) 37,762 (20.5)
    1–5 time 122 (90.6) 36,909 (97.8)
4.7 (2.1–10.4)
    >5 times 14 (9.4) 854 (2.2)
Did child receive care at home in last 12 months
  No 397 (95.1) 177,823 (99.1)
5.7 (3.3–9.7)
  Yes 20 (4.9) 1,588 (0.9)
    1–5 times 3 (20.6) 690 (58.1)
5.3 (1.3–22.6)
    >5 times 12 (79.4) 473 (41.9)
Has child seen a health care professional in doctor’s office or clinic in last 12 months
  No 18 (4.0) 21,744 (11.6)
3.2 (1.7–6.0)
  Yes 398 (96.0) 156,057 (88.4)
    1–5 times 253 (64.8) 130,971 (83.9)
2.8 (2.2–3.7)
    >5 times 145 (35.2) 25,086 (16.1)
Time since child last saw or talked to a doctor or other healthcare provider
  ≥6 months 56 (10.9) 43,407 (24.4)
2.6 (1.8–3.8)
  <6 months 360 (89.1) 134,800 (75.6)
*
Data source: CDC/NCHS, National Health Interview Survey
**
only asked of those 3–17 years of age
^
Pediatrics, family or internal medicine physicians
CHD: congenital heart disease; ASD: autism spectrum disorders; ADHD: attention-deficit/hyperactivity disorder; ADD: attention-deficit disorder; 
SC: sample child; ER: emergency room; CI: confidence interval; CDC: Center for Disease Control and Prevention; NCHS: National Center for 
Health Statistics
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